Ozempic carries real risks, but for most people using it as prescribed, it is not considered dangerous. The drug has a boxed warning from the FDA for thyroid tumor risk, and it can cause serious gastrointestinal complications in rare cases. At the same time, the largest clinical trial to date found that semaglutide (the active ingredient in Ozempic) actually reduced the risk of heart attacks and strokes by about 28% in people with obesity and heart disease. The picture is more nuanced than “safe” or “dangerous,” and the answer depends on your specific health profile and why you’re taking it.
The FDA’s Most Serious Warning
Ozempic’s prescribing label includes a boxed warning, the FDA’s strongest safety alert, about the risk of thyroid C-cell tumors. This concern comes from animal studies where rodents developed medullary thyroid carcinoma (MTC) when given the drug. The warning led the FDA to make Ozempic off-limits for anyone with a personal or family history of MTC or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2.
In humans, the evidence looks different. A large study found no statistically significant increase in overall thyroid cancer risk among people taking GLP-1 drugs like Ozempic. There was a higher rate of thyroid cancer diagnoses in the first 12 months of use, but researchers at the Mayo Clinic attributed this to detection bias: people starting a new medication get more medical attention, including imaging that picks up thyroid nodules that were already there. By 12 months, about 2.1% of Ozempic-class drug users had received a thyroid ultrasound, compared to just 1.5% of people on other diabetes medications. After that first year, the elevated detection rate disappeared entirely. Based on this, routine thyroid screening isn’t recommended solely because you’re on Ozempic.
Gastrointestinal Side Effects
The most common complaints with Ozempic are nausea, vomiting, diarrhea, and constipation. For most people these are mild and fade within a few weeks as the body adjusts, especially during dose increases. But a small number of users develop more serious gut problems.
A study analyzing health insurance records for roughly 16 million U.S. patients found that semaglutide and liraglutide users had 3.67 times the risk of gastroparesis compared to people on other weight-loss medications. Gastroparesis is a condition where the stomach empties too slowly, causing persistent nausea, vomiting, and abdominal pain. The same dataset identified elevated rates of bowel obstruction and pancreatitis. Among roughly 4,800 users of semaglutide or liraglutide examined in one analysis, 73 developed pancreatitis, 73 had bowel obstruction, and 70 experienced gastroparesis. For comparison, among 654 people taking a different weight-loss drug (bupropion-naltrexone), those numbers were 1, 2, and 3 respectively.
These complications are rare in absolute terms, but with tens of millions of prescriptions written worldwide, even a small percentage translates to a large number of affected people. Persistent vomiting, severe abdominal pain, or signs of obstruction (inability to pass gas or stool, cramping that comes in waves) are reasons to seek medical attention promptly.
Muscle Loss During Weight Loss
One underappreciated concern is how much muscle you lose alongside fat. In the landmark STEP-1 trial, participants lost an average of 15.3 kg (about 34 pounds) on semaglutide. Of that, roughly 6.9 kg (about 15 pounds) was lean mass, meaning approximately 45% of the total weight lost came from muscle and other non-fat tissue. That ratio is notably higher than the general rule of thumb in weight loss research, which predicts about one-quarter of lost weight comes from lean tissue.
Losing that much muscle matters because muscle supports metabolism, joint stability, bone density, and overall physical function, particularly as you age. This is why many doctors now recommend strength training and adequate protein intake alongside Ozempic or similar drugs. The weight on the scale may look great, but preserving muscle is critical to making that weight loss healthy in the long run.
Heart Health: Where Ozempic Shines
The SELECT trial, one of the largest studies of semaglutide in people with obesity and existing cardiovascular disease, found that the drug reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke. The overall risk reduction was 28%, and the benefit held up across subgroups, including people with heart failure. Patients with reduced heart pumping ability saw a 35% lower risk of major cardiac events, and those with preserved pumping function saw a 31% reduction.
Serious adverse events were actually less common in the semaglutide group than in the placebo group, with cardiac problems being the most frequent serious event in both groups. However, more people on semaglutide stopped taking the drug due to side effects, mostly gastrointestinal ones. So while the heart benefits are robust, tolerability remains a practical barrier for some users.
Eye Health in People With Diabetes
Early studies raised concern that semaglutide might worsen diabetic retinopathy, a complication that damages blood vessels in the eye. This worry stemmed from the observation that rapid improvements in blood sugar can sometimes trigger a temporary worsening of eye disease. A three-year study found that the risk of retinopathy progression depended heavily on how advanced the eye disease was at baseline. For people with mild or no retinopathy, the three-year progression rate was just 2.7%. For those with more advanced disease, it climbed to 28% or even 45%.
Importantly, the study concluded that semaglutide itself was not associated with an increased risk of progression, visual loss, or need for additional eye treatments over three years. Vision remained stable for about 72% of patients, with 16% experiencing some loss and nearly 12% actually improving. If you have diabetes and existing eye disease, your doctor will likely monitor your eyes more closely when starting Ozempic, but the drug doesn’t appear to make things worse on its own.
Suicidal Thoughts: Concern Resolved
Reports of suicidal thoughts in some GLP-1 drug users prompted both the FDA and European regulators to investigate. The FDA’s review was extensive: a meta-analysis of 91 placebo-controlled trials covering nearly 108,000 patients found no increased risk of suicidal ideation or behavior, depression, anxiety, irritability, or psychosis. A separate real-world study using insurance claims data from over 2.2 million patients reached the same conclusion. Based on this evidence, the FDA in 2025 requested that manufacturers remove suicidal ideation warnings from the labels of GLP-1 drugs including Wegovy (which uses the same ingredient as Ozempic at a higher dose).
Who Should Not Take Ozempic
Ozempic is contraindicated in two specific groups: people with a personal or family history of medullary thyroid carcinoma, and people with Multiple Endocrine Neoplasia syndrome type 2. It’s also off-limits for anyone who has had a serious allergic reaction to semaglutide or any of its inactive ingredients.
Beyond formal contraindications, the risk-benefit calculation shifts depending on why you’re using it. For someone with type 2 diabetes or obesity-related cardiovascular disease, the proven heart benefits and blood sugar control may clearly outweigh the small risks of rare complications. For someone using it purely for cosmetic weight loss without significant metabolic disease, the same rare risks of pancreatitis, gastroparesis, or bowel obstruction carry more weight because there’s less medical upside to offset them. A September 2025 FDA warning letter to Novo Nordisk cited the company for promotional materials that downplayed these serious risks, reinforcing that the dangers, while uncommon, are real and shouldn’t be minimized.